EMPLOYMENT AGREEMENTEmployment Agreement • June 16th, 2020 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
This EMPLOYMENT AGREEMENT (this “Agreement”), dated April 8, 2016 and effective on the date of consummation of the initial closing of the private placement offering of the Company’s common stock (the “Effective Date”), is by and between ADGERO BIOPHARMACEUTICALS HOLDINGS, INC., a Delaware corporation (the “Company”) and Steven J. Rychnovsky (the “Executive”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • June 16th, 2020 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), dated as of March 1, 2018 (the “Effective Date”) is by and between ADGERO BIOPHARMACEUTICALS HOLDINGS, INC., a Delaware corporation (the “Company”) and John Liatos (the “Employee”).
STOCKHOLDER SUPPORT AGREEMENTStockholder Support Agreement • June 16th, 2020 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS STOCKHOLDER SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of [●], 2020, by and among DelMar Pharmaceuticals, Inc., a Nevada corporation (“Parent”), and each of the undersigned stockholders (each, a “Holder”) of Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”).
AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENTEmployment Agreement • June 16th, 2020 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 2 (the “Amendment”) to that certain Employment Agreement, dated April 8, 2016 as amended February 8, 2017 (the “Employment Agreement”), by and between Steven Rychnovsky (the “Executive”) and Adgero Biopharmaceuticals Holdings, Inc. (the “Company”), is effective as of April 6, 2018.
AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENTEmployment Agreement • June 16th, 2020 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 3 (the “Amendment”) to that certain Employment Agreement, dated April 8, 2016 as amended February 8, 2017 and April 6, 2018 (the “Employment Agreement”), by and between Steven Rychnovsky (the “Executive”) and Adgero Biopharmaceuticals Holdings, Inc. (the “Company’’), is effective as of April 6, 2020.
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT, INCENTIVE STOCK OPTION GRANT AGREEMENT AND NONQUALIFIED STOCK OPTION GRANT AGREEMENTEmployment Agreement, Incentive Stock Option Grant Agreement • June 16th, 2020 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 1 (the “Amendment”) to that certain Employment Agreement (the “Employment Agreement”) by and between Steve Rychnovsky (the “Employee”) and Adgero Biopharmaceuticals Holdings, Inc. (the “Company”) and to that certain Incentive Stock Option Grant Agreement (the “ISO Agreement”) by and between the Employee and the Company and to that certain Nonqualified Stock Option Grant Agreement (the “NQSO Agreement”) by and between the Employee and the Company, is effective as of February 8, 2017.
AMENDMENT TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • June 16th, 2020 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations
This AMENDMENT to the ASSET PURCHASE AGREEMENT (this “Amendment”) is made as of May 12, 2014 (the “Effective Date”), by and between ADGERO BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Buyer”) and ST. CLOUD INVESTMENTS, LLC, a limited liability corporation incorporated in the British Virgin Islands (the “Seller”). Capitalized terms used and not defined in this Amendment have the meanings given to them in the APA.
